Not checked for notices yet.
A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors
Maxim Kebenko, Marie-Elisabeth Goebeler, Martin Wolf and 14 more
OncoImmunology · 2018
doi:10.1080/2162402x.2018.1450710
Cited by papers we hold 5
- Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies · 2023No notice
- Recent advances in systemic therapy for hepatocellular carcinoma · 2022No notice
- CAR-T cell combination therapy: the next revolution in cancer treatment · 2022No notice
- Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors · 2021No notice
- Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma · 2020No notice
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.